Specialty Pharmacy

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, addresses how the treatment of advanced cutaneous T cell lymphoma has changed in recent years and whether there have been any advancements of note.

ALS results in muscles that are reduced in size (atrophic), weak, and soft, or muscles that are stiff, tight, and spastic.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, provides an overview of key trials that have been conducted in the advanced cutaneous T cell lymphoma space in recent years.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, explained whether the current advanced cutaneous T cell lymphoma (CTCL) treatment strategies available are applicable for all patients with advanced CTCL and how patients are selected for treatment.

The results of 3 phase 3 trials showed that the drug offered greater proportions of individuals with the condition who met the endpoints of clinical remission and endoscopic response.

Lauren C. Pinter-Brown, MD, FACP, of UCI Health and Chao Family Comprehensive Cancer Center, described what advanced cutaneous T cell lymphoma is in terms of classification and what current treatment approaches are available.

An anti-vascular endothelial growth factor therapy, ranibizumab prevents vision loss in patients with retinal vascular disorders, which can cause irreversible blindness or visual impairments in adults.

REMS are not intended to minimize all harmful effects of a drug, but instead focus on preventing, tracking, and handling a specific serious risk by informing, educating, and/or enforcing measures that reduce the frequency and/or intensity of the event.

Apalutamide (Erleada, Johnson & Johnson) demonstrated a strong prostate-specific antigen response and high adherence rates in patients with non-metastatic castration-resistant prostate cancer.

Tucatinib is indicated to treat adults with advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer who have already received at least 1 anti-HER2-based regimen in the metastatic setting.

In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers, causing deterioration of the nerves.

Beyond the benefits to the pharmacist profession, granting provider status to pharmacists addresses the larger societal problem of growing physician shortages.

Lola Fashoyin-Aje, MD, MPH, associate director of Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence, discusses the importance of promoting inclusion of members of racial and ethnic minority groups in cancer drug trials.

The results of a new study show a new view of genetic regulation by uncovering how genes and disease are related.

As specialty drugs move through clinical trials and preparations for commercialization begin, significant attention is warranted to this process considering the massive investments that would have been already made in the product up to this point.

Harry Webster, RPh, a registered pharmacist at Walgreens and a member of the LGBTQIA+ community, discusses the impact of stigma associated with PrEP and HIV on patients seeking to treat or prevent HIV.

The guidance noted it is preferable for immunocompromised patients to receive their third dose in a health care delivery setting rather than a pharmacy or public vaccination clinic.

The FDA has approved a second drug, zanubritinib, for the treatment of adult patients with Waldenström’s macroglobulinemia.

The FDA has also converted the indication for pembrolizumab from an accelerated to a full, regular approval for patients with urothelial carcinoma.

Experts from Emory Healthcare and Winship Cancer Institute discuss the management of oncology patients by pharmacists within an NCI-designated comprehensive cancer center.

The mutated genes in question, TET2 and DNMT3A, each influence the efficacy of treatment in different ways.

Brad McElya, PharmD, director of specialty health solutions at Walgreens, discusses the critical role pharmacists play in providing HIV prevention drugs in communities across America.

Silmitasertib has produced clinical benefit as a monotherapy and in combination with drugs such as gemcitabine and cisplatin.

Pharmacists can help patients with allergies acquire the right oral antihistamines or decongestants, steroid or decongestant nasal sprays, and/or eye drops based on symptoms.

As the price tags for therapies coming to market have soared into the hundreds of thousands and even millions on occasion, paying for them has become an ever-greater cause of concern and focus area.

Patients with chronic inflammatory demyelinating polyneuropathy who transitioned from intravenous immune globulin to subcutaneous immune globulin showed significantly improved quality-of-life measures.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Cheryl Larson, president and CEO of Midwest Business Group on Health, discusses current efforts to manage drug spend and the high cost of specialty drugs on the market.